Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

拉米夫定 医学 胃肠病学 内科学 HBeAg 聚乙二醇干扰素α-2a 乙型肝炎 安慰剂 联合疗法 乙型肝炎病毒 慢性肝炎 免疫学 乙型肝炎表面抗原 病毒 利巴韦林 病理 替代医学
作者
Patrick Marcellin,George K. K. Lau,Ferruccio Bonino,Patrizia Farci,Stephanos J. Hadziyannis,Rui Jin,Zhi-Meng Lu,Teerha Piratvisuth,Georgios Germanidis,Cihan Yurdaydin,Moisés Diago,Selim Gürel,Ming-Yang Lai,Peter Button,Nigel Pluck
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:351 (12): 1206-1217 被引量:1032
标识
DOI:10.1056/nejmoa040431
摘要

Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.We compared the efficacy and safety of peginterferon alfa-2a (180 microg once weekly) plus placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), and lamivudine alone in 177, 179, and 181 patients with HBeAg-negative chronic hepatitis B, respectively. Patients were treated for 48 weeks and followed for an additional 24 weeks.After 24 weeks of follow-up, the percentage of patients with normalization of alanine aminotransferase levels or hepatitis B virus (HBV) DNA levels below 20,000 copies per milliliter was significantly higher with peginterferon alfa-2a monotherapy (59 percent and 43 percent, respectively) and peginterferon alfa-2a plus lamivudine (60 percent and 44 percent) than with lamivudine monotherapy (44 percent, P=0.004 and P=0.003, respectively; and 29 percent, P=0.007 and P=0.003, respectively). Rates of sustained suppression of HBV DNA to below 400 copies per milliliter were 19 percent with peginterferon alfa-2a monotherapy, 20 percent with combination therapy, and 7 percent with lamivudine alone (P<0.001 for both comparisons with lamivudine alone). Loss of hepatitis B surface antigen occurred in 12 patients in the peginterferon groups, as compared with 0 patients in the group given lamivudine alone. Adverse events, including pyrexia, fatigue, myalgia, and headache, were less frequent with lamivudine monotherapy than with peginterferon alfa-2a monotherapy or combination therapy.Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine. The addition of lamivudine to peginterferon alfa-2a did not improve post-therapy response rates.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梦酱完成签到,获得积分20
刚刚
共享精神的应助被胡萝卜卜采纳,获得10
刚刚
152455发布了新的文献求助30
刚刚
刚刚
平p发布了新的文献求助20
1秒前
1秒前
yusuf完成签到,获得积分10
2秒前
surain发布了新的文献求助10
2秒前
奥美拉唑发布了新的文献求助20
2秒前
youyou完成签到,获得积分20
3秒前
自由的纲发布了新的文献求助10
3秒前
斯文败类的应助被七月晴采纳,获得10
3秒前
4秒前
笑呵呵完成签到,获得积分10
4秒前
4秒前
勤恳的香之完成签到,获得积分20
5秒前
Ava的应助被自觉邪欢采纳,获得10
5秒前
开朗尔蓝发布了新的文献求助10
6秒前
6秒前
彭于晏的应助被swimming采纳,获得10
6秒前
luox发布了新的文献求助10
7秒前
8秒前
8秒前
汉堡包的应助被勤恳的香之采纳,获得10
8秒前
酷波er的应助被yuanjie周采纳,获得10
9秒前
9秒前
11秒前
三年两篇以上一区SCI完成签到,获得积分10
11秒前
wanci的应助被Vibe采纳,获得10
11秒前
12秒前
12秒前
12秒前
王123发布了新的文献求助10
13秒前
pp完成签到,获得积分10
13秒前
14秒前
Eli发布了新的文献求助100
14秒前
14秒前
14秒前
TT完成签到 ,获得积分10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170866
求助须知:如何正确求助?哪些是违规求助? 9563691
关于积分的说明 21771699
捐赠科研通 7762353
什么是DOI,文献DOI怎么找? 3430767
关于科研通互助平台的介绍 2554622
邀请新用户注册赠送积分活动 2475597